Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients
Abstract Objective. This study was aimed to evaluate the prevalence of Cushing’s syndrome and the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients. Methods. Anthropometric measurements and other laboratory data, including 1 mg dexamethasone suppression test of 753 class 3 obese patients, who applied to the Endocrinology and Metabolism Outpatient Clinic for the pre-bariatric surgery evaluation between 2011 and 2020, were evaluated retrospectively. Results. An abnormal response to the 1 mg dexamethasone suppression test (cortisol ≥1.8 mcg/dl) was observed in 24 patients and the presence of Cushing’s syndrome was confirmed by additional tests in 6 patients. The prevalence of abnormal dexamethasone suppression test was 3.18% and the prevalence of Cushing’s syndrome 0.79%. The specificity value was determined as 97.5% for 1 mg dexamethasone suppression test with cortisol threshold value ≥1.8 mcg/dl. Conclusions. The prevalence of Cushing’s syndrome was found to be low in class 3 obese patients and 1 mg of dexamethasone suppression test had a very sufficient performance for Cushing’s syndrome screening in this patient group..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
---|---|
Enthalten in: |
Endocrine regulations - 56(2022), 4 vom: 01. Okt., Seite 265-270 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Baldane, Suleyman [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: |
---|
Anmerkungen: |
© 2022 Suleyman Baldane et al., published by Sciendo |
---|
doi: |
10.2478/enr-2022-0028 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2142932495 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2142932495 | ||
003 | DE-627 | ||
005 | 20230813183055.0 | ||
007 | tu | ||
008 | 230813s2022 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.2478/enr-2022-0028 |2 doi | |
035 | |a (DE-627)OLC2142932495 | ||
035 | |a (DE-B1597)enr-2022-0028-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.00$jMedizin: Allgemeines |2 bkl | ||
100 | 1 | |a Baldane, Suleyman |e verfasserin |4 aut | |
245 | 1 | 0 | |a Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © 2022 Suleyman Baldane et al., published by Sciendo | ||
520 | |a Abstract Objective. This study was aimed to evaluate the prevalence of Cushing’s syndrome and the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients. Methods. Anthropometric measurements and other laboratory data, including 1 mg dexamethasone suppression test of 753 class 3 obese patients, who applied to the Endocrinology and Metabolism Outpatient Clinic for the pre-bariatric surgery evaluation between 2011 and 2020, were evaluated retrospectively. Results. An abnormal response to the 1 mg dexamethasone suppression test (cortisol ≥1.8 mcg/dl) was observed in 24 patients and the presence of Cushing’s syndrome was confirmed by additional tests in 6 patients. The prevalence of abnormal dexamethasone suppression test was 3.18% and the prevalence of Cushing’s syndrome 0.79%. The specificity value was determined as 97.5% for 1 mg dexamethasone suppression test with cortisol threshold value ≥1.8 mcg/dl. Conclusions. The prevalence of Cushing’s syndrome was found to be low in class 3 obese patients and 1 mg of dexamethasone suppression test had a very sufficient performance for Cushing’s syndrome screening in this patient group. | ||
700 | 1 | |a Celik, M |4 aut | |
700 | 1 | |a Kebapcilar, Levent |4 aut | |
700 | 1 | |a Ipekci, Suleyman Hilmi |4 aut | |
700 | 1 | |a Abusoglu, Sedat |4 aut | |
700 | 1 | |a Yilmaz, Huseyin |4 aut | |
700 | 1 | |a Alptekin, Husnu |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Endocrine regulations |d Sciendo, 1991 |g 56(2022), 4 vom: 01. Okt., Seite 265-270 |w (DE-627)170619117 |w (DE-600)1082213-6 |w (DE-576)026374145 |x 1210-0668 |7 nnns |
773 | 1 | 8 | |g volume:56 |g year:2022 |g number:4 |g day:01 |g month:10 |g pages:265-270 |
856 | 4 | 1 | |u https://doi.org/10.2478/enr-2022-0028 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
936 | b | k | |a 44.00$jMedizin: Allgemeines |q VZ |0 106409646 |0 (DE-625)106409646 |
951 | |a AR | ||
952 | |d 56 |j 2022 |e 4 |b 01 |c 10 |h 265-270 |